Taysha Gene Therapies Net Change in Long-Term Investments 2020-2025 | TSHA
Taysha Gene Therapies net change in long-term investments from 2020 to 2025. Net change in long-term investments can be defined as the net cash flows from the sale and purchase of investments with maturities greater than one year.
Taysha Gene Therapies Annual Net Change in Long-Term Investments
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$N/A |
| 2020 |
$N/A |
| 2019 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.599B |
$0.008B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
